Monte Rosa Therapeutics (NASDAQ:GLUE) Receives Buy Rating from Guggenheim

Monte Rosa Therapeutics (NASDAQ:GLUE)‘s stock had its “buy” rating reissued by Guggenheim in a research note issued to investors on Tuesday,Benzinga reports. They currently have a $28.00 target price on the stock. Guggenheim’s price target indicates a potential upside of 103.34% from the stock’s previous close.

Other research analysts have also recently issued reports about the stock. JPMorgan Chase & Co. lowered their target price on shares of Monte Rosa Therapeutics from $31.00 to $27.00 and set an “overweight” rating on the stock in a report on Friday, August 7th. Weiss Ratings cut Monte Rosa Therapeutics from a “sell (d+)” rating to a “sell (d)” rating in a research note on Tuesday, August 11th. Wedbush reduced their price target on Monte Rosa Therapeutics from $37.00 to $27.00 and set an “outperform” rating on the stock in a research report on Monday, August 3rd. TD Cowen upgraded Monte Rosa Therapeutics to a “strong-buy” rating in a research note on Monday. Finally, Zacks Research raised Monte Rosa Therapeutics from a “strong sell” rating to a “hold” rating in a report on Tuesday, August 4th. One research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Monte Rosa Therapeutics presently has a consensus rating of “Moderate Buy” and an average price target of $28.50.

Monte Rosa Therapeutics Stock Performance

Shares of Monte Rosa Therapeutics stock opened at $13.77 on Tuesday. The firm has a 50-day moving average of $20.04 and a 200-day moving average of $18.77. Monte Rosa Therapeutics has a 52-week low of $4.54 and a 52-week high of $25.77. The stock has a market cap of $1.17 billion, a PE ratio of -7.82 and a beta of 1.59.

Monte Rosa Therapeutics (NASDAQ:GLUE) last released its quarterly earnings results on Thursday, August 6th. The company reported ($0.43) EPS for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.05). Monte Rosa Therapeutics had a negative return on equity of 43.31% and a negative net margin of 560.85%.The business had revenue of $8.97 million for the quarter, compared to the consensus estimate of $12.91 million. Equities research analysts predict that Monte Rosa Therapeutics will post -1.32 earnings per share for the current fiscal year.

Insider Activity

In related news, COO Jennifer Champoux sold 2,176 shares of Monte Rosa Therapeutics stock in a transaction that occurred on Wednesday, June 17th. The shares were sold at an average price of $19.00, for a total value of $41,344.00. Following the transaction, the chief operating officer directly owned 62,371 shares of the company’s stock, valued at $1,185,049. This trade represents a 3.37% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Sharon Townson sold 6,000 shares of Monte Rosa Therapeutics stock in a transaction that occurred on Monday, July 6th. The shares were sold at an average price of $23.31, for a total transaction of $139,860.00. Following the completion of the transaction, the insider directly owned 67,845 shares in the company, valued at $1,581,466.95. This trade represents a 8.13% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 81,778 shares of company stock valued at $1,768,581 over the last quarter. 6.40% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Monte Rosa Therapeutics

A number of large investors have recently modified their holdings of GLUE. Allworth Financial LP bought a new position in shares of Monte Rosa Therapeutics in the 2nd quarter valued at $30,000. Mirae Asset Global Investments Co. Ltd. raised its holdings in shares of Monte Rosa Therapeutics by 32.5% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,164 shares of the company’s stock worth $50,000 after buying an additional 776 shares in the last quarter. Seven Fleet Capital Management LP bought a new stake in shares of Monte Rosa Therapeutics during the 4th quarter worth $63,000. Russell Investments Group Ltd. bought a new stake in shares of Monte Rosa Therapeutics during the 3rd quarter worth $32,000. Finally, E Fund Management Co. Ltd. acquired a new stake in Monte Rosa Therapeutics in the second quarter valued at about $200,000. Institutional investors and hedge funds own 79.96% of the company’s stock.

About Monte Rosa Therapeutics

Monte Rosa Therapeutics is a biotechnology company focused on accelerating drug discovery through the integration of single-cell genomics and artificial intelligence. Founded in 2020 and headquartered in Cambridge, Massachusetts, the company has built a proprietary platform designed to identify novel therapeutic targets and optimize lead candidates for areas of high unmet medical need. By combining cutting-edge computational methods with comprehensive cellular profiling, Monte Rosa aims to streamline the preclinical development process and uncover insights into disease biology that might otherwise remain hidden.

The company’s main business activities center on using its AI-driven discovery engine to pursue programs in immuno-oncology and neuroscience.